AI Summary & Key Takeaways
AI InsightConclusion: Secukinumab appears to be a safe and effective treatment option in selected patients with treatment naive to anti- TNFs or in patients with AS and PsA who could not use it due to unresponsiveness and/or intolerance.
📌 3 Key Takeaways
Abstract
Objective: Secukunimab is a fully human monoclonal antibody to IgG1-kappa that binds to IL-17A and its long-term data are well known. However, real-life data on treatment outcomes are limited in our country. In our study, we aimed to evaluate the early results of secukinumab, which is relatively newly used in our country, in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA), who were followed up in our clinic. Methods: Forty-four patients were included in the study with the diagnosis of AS and PsA. Secukinumab treatment was started between May 2018 and October 2019, and their data were analyzed retrospectively. Results: The mean age of patients was 44.9 years and most of them were male (61.4%). Secukinumab treatment was initiated in 33 AS (75%) and 11 (25%) PsA patients. The mean duration of secukinumab treatment was 9.1±5.3 months in AS and 7.0±4.0 months in PsA. The continuation rate of secukinumab was 75.7% (n=25) in AS and 63.6% (n=7) in PsA. No severe infection or malignancy development was observed during secukinumab treatment in the follow-up period. Conclusion: Secukinumab appears to be a safe and effective treatment option in selected patients with treatment naive to anti- TNFs or in patients with AS and PsA who could not use it due to unresponsiveness and/or intolerance.
Özet
Amaç: Sekukunimab IL-17A’ya bağlanan IgG1-kappa tam insan monoklonal antikorudur ve uzun dönem verileri bilinmektedir. Ülkemizde ise tedavi sonuçlarıyla ilgili gerçek yaşam verisi kısıtlıdır. Çalışmamızda ülkemizde görece yeni kullanıma giren sekukinumabın kliniğimizden takipli ankilozan spondilit (AS) ve psöriyatik artrit (PsA) hastalarındaki erken dönem sonuçlarını değerlendirmeyi amaçladık. Yöntem: Çalışmamıza Mayıs 2018-Ekim 2019 tarihleri arasında sekukinumab tedavisi başlanan AS ve PsA tanılarıyla polikliniğimizden izlenen 44 hasta dahil edilmiş olup verileri retrospektif olarak incelenmiştir. Bulgular: Çalışmaya dahil edilen 44 hastanın ortalama yaşı 44,9 olup çoğunluğu erkekti (%61,4). Otuz üç AS (%75) ve 11 (%25) PsA hastasında sekukinumab tedavisine başlandı. Sekukinumab tedavi süresi AS’de ortalama 9,1±5,3 ay, PsA’da ise ortalama 7,0±4,0 aydır. Sekukinumab devam oranı AS’de %75,7 (n=25) olurken PsA’da %63,6 (n=7) olarak gerçekleşmiştir. Sekukinumab tedavisi altında ciddi enfeksiyon veya malignite gelişimine takip süresince rastlanmamıştır. Sonuç: Sekukinumab AS ve PsA’da anti-TNF kullanmamış ya da yanıtsızlık ve/veya intolerans nedeniyle kullanamayan seçilmiş hastalarda etkin ve güvenilir bir tedavi seçeneği olarak görünmektedir.